A Study of Dulaglutide in Chinese Participants

NCT01667900 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of dulaglutide, a medication, in Chinese adults with type 2 diabetes and healthy volunteers to measure how the drug is absorbed and processed by the body.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 58 people

Who can join Ages 18–75 · all sexes Healthy volunteers accepted.

Timeline Started 2012-08 · est. completion 2014-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT01667900 ↗

Description as written by the study sponsor.

This is a study of dulaglutide in Chinese participants. The purpose of the study is to determine how the body processes dulaglutide and how dulaglutide affects the body. This study has 2 parts: Part A - single dose of dulaglutide administered to healthy participants in 2 of 3 study periods. There is a minimum 28-day washout between periods. Part A will last approximately 16 weeks. Part B - multiple doses of dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM). Part B will last approximately 15 weeks. Doses of 0.5 milligrams (mg), 0.75 mg, and 1.5 mg of dulaglutide will be evaluated in this study.

Treatments tested

Dulaglutide also known as LY2189265 Drug
Placebo Drug

Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.

Main thing measured	Pharmacokinetics: Maximum Concentration (Cmax) of Dulaglutide
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2, Healthy Volunteers
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01667900 ↗